Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash

• Deal expected to reduce GAAP and non-gaap EPS by USD 0.79-0.83 in Q4 2026.

Bolt-on licensing and asset acquisitions have been the standard playbook for large-cap pharma buyers managing patent exposure and replenishing mid-stage pipelines, and Gilead has prior form in paying upfront cash for single-asset inflammation and oncology programs rather than pursuing transformational deals. The structure here, upfront cash with an explicitly quantified EPS drag, follows the usual sequence for deals of this type: an immediate accounting charge, then a long gap before the asset either advances through the clinic or is written down, which is where the real value determination occurs. An oral IL-23R program sits in a crowded immunology field where injected incumbents have set a high efficacy bar, so the differentiation question for the lead asset is whether oral delivery buys adherence and share at comparable efficacy, a distinction that has separated winners from also-rans in prior oral-versus-biologic contests. The worth-watching items are the development timeline and any milestone or royalty tail disclosed alongside the upfront figure, the target's prior clinical data quality, and whether the buyer's commentary frames this as pipeline maintenance or as a strategic push into immunology. Reaction in the acquirer on deals of this size has historically been muted relative to the market cap, with the accounting impact disclosed up front tending to be absorbed quickly.